![Silibinin inhibits ultraviolet B radiation‐induced mast cells recruitment and bone morphogenetic protein 2 expression in the skin at early stages in Ptch(+/−) mouse model of basal cell carcinoma - Rigby - 2019 - Silibinin inhibits ultraviolet B radiation‐induced mast cells recruitment and bone morphogenetic protein 2 expression in the skin at early stages in Ptch(+/−) mouse model of basal cell carcinoma - Rigby - 2019 -](https://onlinelibrary.wiley.com/cms/asset/b8ddf9b0-78e4-40f1-9090-9b043ffba16f/mc23008-fig-0003-m.png)
Silibinin inhibits ultraviolet B radiation‐induced mast cells recruitment and bone morphogenetic protein 2 expression in the skin at early stages in Ptch(+/−) mouse model of basal cell carcinoma - Rigby - 2019 -
![Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm - Arend - 2018 - The Oncologist - Wiley Online Library Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm - Arend - 2018 - The Oncologist - Wiley Online Library](https://theoncologist.onlinelibrary.wiley.com/cms/asset/6b66c5af-6920-48db-a7a9-1038c63043fb/onco12670-tbl-0002.png)
Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm - Arend - 2018 - The Oncologist - Wiley Online Library
![Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens - ScienceDirect Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2589004221007252-fx1.jpg)
Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens - ScienceDirect
![Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies - Gynecologic Oncology Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies - Gynecologic Oncology](https://www.gynecologiconcology-online.net/cms/asset/8c885a95-2b5f-4211-b9b6-bd15ad133f73/gr1.jpg)
Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies - Gynecologic Oncology
![Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm - Arend - 2018 - The Oncologist - Wiley Online Library Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm - Arend - 2018 - The Oncologist - Wiley Online Library](https://theoncologist.onlinelibrary.wiley.com/cms/asset/cc0857e3-e23a-46db-abe2-daf5cb8c5154/onco12670-tbl-0004.png)
Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm - Arend - 2018 - The Oncologist - Wiley Online Library
![The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms | Leukemia The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms | Leukemia](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41375-022-01620-2/MediaObjects/41375_2022_1620_Fig2_HTML.png)
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms | Leukemia
![The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms | Leukemia The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms | Leukemia](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41375-022-01620-2/MediaObjects/41375_2022_1620_Fig1_HTML.png)
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms | Leukemia
![Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial - The Lancet Oncology Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/f24735fe-5a29-4c5e-87e5-fc0223167fce/gr1_lrg.jpg)
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial - The Lancet Oncology
![A systematic summary of survival and death signalling during the life of hair follicle stem cells | Stem Cell Research & Therapy | Full Text A systematic summary of survival and death signalling during the life of hair follicle stem cells | Stem Cell Research & Therapy | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13287-021-02527-y/MediaObjects/13287_2021_2527_Fig7_HTML.png)
A systematic summary of survival and death signalling during the life of hair follicle stem cells | Stem Cell Research & Therapy | Full Text
![Frontiers | Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases Frontiers | Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases](https://www.frontiersin.org/files/Articles/273558/fmed-04-00073-HTML/image_m/fmed-04-00073-g001.jpg)
Frontiers | Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases
![Cancers | Free Full-Text | Comparative Evaluation of Tumor-Infiltrating Lymphocytes in Companion Animals: Immuno-Oncology as a Relevant Translational Model for Cancer Therapy Cancers | Free Full-Text | Comparative Evaluation of Tumor-Infiltrating Lymphocytes in Companion Animals: Immuno-Oncology as a Relevant Translational Model for Cancer Therapy](https://www.mdpi.com/cancers/cancers-14-05008/article_deploy/html/images/cancers-14-05008-g001.png)